StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) bonds

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)

Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Total debt
$1.13B
$448.31M due within a year
Net debt
$1.07B
After $55.96M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
8.7×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2012

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Ligand Pharmaceuticals's 10-Q for the period ended Sep 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Convertible Senior Notes due 2030
Convertible at $253 a share
0.75%2030$460.00M$460.00M
Convertible Senior Notes due 2030 - Initial Purchase Option
Convertible
–2030$60.00M–
Convertible Senior Notes due 2031
Convertible at $334 a share
0.00%2031$700.00M$700.00M
Convertible Senior Notes due 2031 - Initial Purchase Option
Convertible
–2031$75.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailableDrawn
Revolving Credit Facility$125.00M––
Revolving Credit Facility$125.00M$124.40M$0

See a number that looks wrong?